Maple Capital Management Inc. Lowers Position in Danaher Corporation $DHR

Key Points

• Maple Capital Management Inc. has reduced its stake in Danaher Corporation by 31.7%, holding 11,285 shares valued at approximately $2.31 million.
• Institutional investors own 79.05% of Danaher’s stock, indicating strong institutional confidence in the company.
• Danaher recently declared a quarterly dividend of $0.32 per share, with an annualized yield of 0.7% and a pay date set for October 31st.

Maple Capital Management Inc. decreased its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 31.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,285 shares of the conglomerate's stock after selling 5,230 shares during the period. Maple Capital Management Inc.'s holdings in Danaher were worth $2,313,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of DHR. Nuveen LLC bought a new stake in Danaher during the first quarter worth about $833,941,000. GAMMA Investing LLC boosted its position in shares of Danaher by 24,958.2% in the 1st quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after purchasing an additional 1,863,381 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Danaher by 4,248.8% in the 4th quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after purchasing an additional 1,601,800 shares in the last quarter. Invesco Ltd. boosted its holdings in Danaher by 44.5% in the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock worth $965,259,000 after acquiring an additional 1,450,703 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its stake in shares of Danaher by 460.6% in the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate's stock worth $309,558,000 after buying an additional 1,107,998 shares in the last quarter. 79.05% of the stock is owned by institutional investors.

Danaher Stock Performance

Shares of DHR stock traded up $1.89 on Tuesday, hitting $190.43. The company had a trading volume of 4,812,269 shares, compared to its average volume of 4,147,311. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The company has a 50-day moving average price of $200.98 and a 200-day moving average price of $198.64. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The firm has a market cap of $136.36 billion, a P/E ratio of 40.52, a price-to-earnings-growth ratio of 2.65 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The company's revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio is presently 27.23%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on DHR shares. Wells Fargo & Company lowered their price objective on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a research report on Wednesday, July 23rd. Robert W. Baird increased their price objective on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research note on Friday, July 18th. Evercore ISI lowered their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. Scotiabank upgraded shares of Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Seventeen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and a consensus target price of $246.35.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the sale, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 11.20% of the stock is owned by company insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.